Physician profile
Mark S Brown
NPI 1114999729
$42,481.74
in general payments reported to CMS, 2019-2025
9 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.28 · 2020: $23K · 2021: $9,262 · 2022: $2,619 · 2023: $5,965 · 2024: $768 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,210 · Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,209.68 |
| Food and Beverage | $2,026.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $40,878.15 | 2019-2023 | Tepezza |
| Amgen INC. | $1,165.58 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $220.61 | 2022-2024 | Precision 1, Dailies Total1, Total30 |
| Sun Pharmaceutical Industries INC. | $115.33 | 2022-2023 | Cequa |
| Merz Pharmaceuticals, LLC | $33.75 | 2022 | |
| Merz North America, INC. | $19.72 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.01 | 2024 | Exparel |
| Bausch & Lomb Americas INC. | $17.35 | 2024 | Miebo |
| Aerie Pharmaceuticals, INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.